PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy

Overview of attention for article published in Frontiers in immunology, March 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Readers on

mendeley: 20 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 33,309 followers.

RT @FrontImmunol: New Research: PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy: I…

04 Mar 2022

Reply Repost Favourite

RT @FrontImmunol: New Research: PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy: I…

03 Mar 2022

Reply Repost Favourite

New Research: PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy: Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a… https://t.co/wttO0

02 Mar 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.